prmaconsulting™
Pricing, reimbursement and market access consulting
Risk Sharing Agreements (RSAs)
RSAs are an increasingly common way of achieving market access through innovative agreements with payers. RSAs are now implemented in countries throughout the world – not just Europe – so RSA contingency planning should be part of any comprehensive market access plan.
prmaconsulting™ can advise on the evaluation, strategy development and implementation of an RSA.
RSA feasibility
- Would an RSA be a useful market access tool for the product?
- Are there useful RSA benchmarks?
- Which countries are likely to favour an RSA?
- What is the process to develop an RSA?
- When should negotiations begin with payers?
RSA strategy development
- What is the appropriate RSA framework for my product?
- What are the outcomes (e.g. financial or clinical) that will be measured?
- How will the RSA be monitored?
- What are the quantitative implications – the cost of implementing the RSA, but also the pharmacoeconomic implications for the product?
- What are the risks of undertaking the RSA?
- When should payer negotiations begin?
RSA implementation
- What is needed to engage with payers?
- How should the RSA be monitored?
- What are the implications for other portfolio products?
Fill in the fields below and press submit. A member of our team
will respond
shortly.
Email: info@prmaconsulting.com
Tel: +44 (0) 1252 786284
Head Office
PRMA Consulting, Centaur House, Ancells Road, Fleet, GU51 2UJ
prmaconsulting™